WME-107

GPTKB entity

Statements (64)
Predicate Object
gptkbp:instanceOf chemical compound
gptkbp:chemicalFormula C12H15N3O2
gptkbp:hasAccessibilityFeatures high
gptkbp:hasAwards specific receptor
gptkbp:hasCharacter Phase II
gptkbp:hasFacility soluble in water
gptkbp:hasFilm nausea
gptkbp:hasMerchandise inhibits enzyme Y
gptkbp:hasMission chronic pain
gptkbp:hasPopulation adults
gptkbp:hasPrograms low toxicity
gptkbp:hasWeight 233.27 g/mol
https://www.w3.org/2000/01/rdf-schema#label WME-107
gptkbp:isAssociatedWith receptor Z
gptkbp:isAttendedBy hospital settings
oral route
clinical settings
clinical trial participants
patients with condition Y
gptkbp:isAvailableIn tablet
gptkbp:isCompatibleWith stable at room temperature
gptkbp:isDocumentedIn clinical guidelines
research publications
clinical trial registries
gptkbp:isEvaluatedBy patient outcomes
safety and efficacy
long-term effects
quality of life improvements
efficacy in pain management
gptkbp:isFundedBy gptkb:ABC_Labs
gptkbp:isInformedBy excipients A and B
gptkbp:isPartOf research studies
clinical trials
alternative therapies
treatment guidelines
therapeutic regimen
therapeutic protocols
drug development pipeline
standard treatment
WME-106
gptkbp:isPortrayedBy clinical research
scientific literature
medical journals
gptkbp:isRegulatedBy gptkb:FDA
gptkbp:isRelatedTo WME-108
gptkbp:isStudiedIn various demographics
Phase III trials
efficacy in various conditions
WME-109
efficacy in specific populations
treatment of disease X
gptkbp:isTrainedIn placebo
gptkbp:isUsedBy healthcare_professionals
gptkbp:isUsedIn medical research
experimental treatments
gptkbp:isUtilizedFor autoimmune diseases
chronic conditions
pain relief
neurological disorders
gptkbp:isUtilizedIn preclinical studies
gptkbp:isVisitedBy gptkb:XYZ_Pharmaceuticals
gptkbp:notableArtists cancer therapy
gptkbp:numberOfFigures 123456-78-9
gptkbp:route intravenous